PharmacoEconomics

Homocyst(e)ine and Coronary Heart Disease: Pharmacoeconomic Support for Interventions to Lower Hyperhomocyst(e)inaemia
pp. 429-442(14)
Authors: Nallamothu B.K.; Fendrick A.M.; Omenn G.S.

Standardisation of Costs: The Dutch Manual for Costing in Economic Evaluations
pp. 443-454(12)
Authors: Oostenbrink J.B.; Koopmanschap M.A.; Rutten F.F.H.

Health-Related Quality of Life and Cost Impact of Irritable Bowel Syndrome in a UK Primary Care Setting
pp. 455-462(8)
Authors: Akehurst R.L.; Brazier J.E.; Mathers N.; O'Keefe C.; Kaltenthaler E.; Morgan A.; Platts M.; Walters S.J.

Limitations of the Methods Used for Calculating Quality-Adjusted Life-Year Values
pp. 463-473(11)
Authors: Duru G.; Auray J.P.; Béresniak A.; Lamure M.; Paine A.; Nicoloyannis N.

A Model to Estimate the Cost Benefit of an Occupational Vaccination Programme for Influenza with Influvac in the UK
pp. 475-484(10)
Authors: Das Gupta R.; Guest J.F.

Cost Effectiveness of Paclitaxel/Cisplatin Compared with Cyclophosphamide/Cisplatin in the Treatment of Advanced Ovarian Cancer in Belgium
pp. 485-497(13)
Authors: Neymark N.; Gorlia T.; Adriaenssen I.; Baron B.; Piccart M.